Results 191 to 200 of about 16,960 (244)

Eplerenone modulates the inflammatory response in monosodium iodoacetate-induced knee osteoarthritis in rats: Involvement of RANKL/OPG axis.

Life Science, 2023
AIMS Osteoarthritis (OA) is a multifactorial degenerative disease marked by the progressive deterioration of articular cartilage with inflammation of the synovium. OA's main symptoms include pain and function loss.
R. Mostafa, A. Salama
semanticscholar   +1 more source

Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study.

European Heart Journal - Cardiovascular Pharmacotherapy, 2023
BACKGROUND The mineralocorticoid receptor antagonists (MRAs) eplerenone and spironolactone are beneficial in heart failure with reduced ejection fraction (HFrEF), but have not been prospectively compared. We compared clinical outcomes, daily dosages, and
J. Larsson, C. Denholt, J. J. Thune, A. Raja, E. Fosbøl, M. Schou, L. Køber, O. W. Nielsen, F. Gustafsson, S. Kristensen   +9 more
semanticscholar   +1 more source

Mineralocorticoid Receptor Antagonism by Eplerenone and Arterial Inflammation in HIV: The MIRABELLA HIV Study.

JAMA cardiology, 2023
Importance The risk for atherosclerotic disease is increased 1.5- to 2.0-fold among persons with HIV (PWH). Increased activation of the renin-angiotensin-aldosterone system may contribute to increased arterial inflammation in this population ...
Suman Srinivasa, S. Abohashem, Allie R. Walpert, Carolyn N Dunderdale, Sanjna Iyengar, Grace Shen, Michael Jerosch-Herold, Christopher R. Defilippi, Gregory K. Robbins, Hang Lee, Raymond Y. Kwong, Gail K. Adler, A. Tawakol, S. Grinspoon   +13 more
semanticscholar   +1 more source

Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial.

American journal of ophthalmology-glaucoma, 2021
PURPOSE To compare the efficacy and safety between half-dose photodynamic therapy (PDT) and eplerenone for treating chronic central serous chorioretinopathy (cCSC). DESIGN Multicenter, open-label, randomized controlled trial.
Thomas J. van Rijssen, E. V. van Dijk, R. Tsonaka, H. M. Feenstra, G. Dijkman, Petrus J. H. Peters, R. Diederen, C. Hoyng, R. Schlingemann, C. Boon   +9 more
semanticscholar   +1 more source

Ethics and eplerenone

Journal of Medical Ethics, 2012
The use of a placebo arm in clinical trials is unethical if there is an active comparator that is acceptably safe and effective. We argue that reasonable evidence of effectiveness and safety of an inexpensive alternative to an expensive therapy is sufficient to require that the inexpensive therapy be included as a comparator when the expensive therapy ...
Shruti, Gupta, Adriane J, Fugh-Berman, Anthony, Scialli   +2 more
openaire   +2 more sources

Eplerenone reduces renal ischaemia/reperfusion injury by modulating Klotho, NF-κB and SIRT1/SIRT3/PGC-1α signalling pathways.

The Journal of pharmacy and pharmacology, 2022
OBJECTIVES Acute kidney injury (AKI) is a sudden impairment in kidney function that is associated with high morbidity and mortality. Inflammation, oxidative stress, mitochondrial impairment and energy depletion, along with organ dysfunction are hallmarks
Alireza Barati, Yalda Rahbar Saadat, Seyed Mohammadmahdi Meybodi, Sana Nouraei, Kimia Moradi, Farid Kamrani Moghaddam, Zahra Malekinejad, Seyed Mahdi Hosseiniyan Khatibi, S. Zununi Vahed, Y. Bagheri   +9 more
semanticscholar   +1 more source

Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR/CTGF pathway.

International Immunopharmacology, 2022
Cardiovascular complications are the leading causes of death in patients with chronic kidney disease (CKD), accounting for approximately 50% of deaths.
Yutong Han, Yunqian Xian, Xiaomeng Gao, Panpan Qiang, Juan-Juan Hao, Fan Yang, T. Shimosawa, Yi-Ran Chang, Qingyou Xu   +8 more
semanticscholar   +1 more source

The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.

JACC. Heart failure
BACKGROUND Fibrosis plays a central role in hypertrophic cardiomyopathy (HCM), contributing to symptoms via impaired systolic and diastolic function and ventricular arrhythmias.
S. Papapostolou, L. Iles, J. O'brien, Sarah Gutman, A. Ellims, James L Hare, D. Stub, S. Moir, Andrew Taylor   +8 more
semanticscholar   +1 more source

When to use either spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases.

Nephrology, Dialysis and Transplantation
Kidney disease frequently coexists with cardiovascular diseases, and this dual presence significantly amplifies the risk of adverse clinical outcomes. Shared pathophysiological mechanisms and common cardiovascular risk factors contribute to the increased
M. Kobayashi, N. Girerd, F. Zannad
semanticscholar   +1 more source

Eplerenone inhibits UUO-induced lymphangiogenesis and cardiac fibrosis by attenuating inflammatory injury.

International Immunopharmacology, 2022
Cardiorenal syndrome (CRS) is the leading cause of death associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). However, the underlying mechanisms of CRS are still poorly understood.
Gege Chen, Yi-Ran Chang, Yun-zhao Xiong, Juan-Juan Hao, Lingjing Liu, Ziqian Liu, Hui Li, Panpan Qiang, Yutong Han, Yunqian Xian, Tatsuo Shimosawa, Xiang-ting Wang, Fan Yang, Qingyou Xu   +13 more
semanticscholar   +1 more source